MedPath

VA Hospital Clinical Trials Suspended Due to DOGE Cuts, Creating Healthcare Crisis for Veterans

• Clinical trials at Veterans Affairs hospitals, including a promising cancer treatment study in Pittsburgh, have been suspended due to staffing shortages caused by the Department of Government Efficiency (DOGE) cuts.

• The Trump administration's hiring freeze has prevented renewal of key research staff positions, halting veterans' access to experimental treatments for conditions like advanced head and neck cancers.

• Over 2,400 VA employees, many veterans themselves, have been fired since Trump's inauguration, affecting critical support services including medical supply procurement, appointment scheduling, and patient transportation.

Veterans Affairs hospitals across the country are facing significant disruptions to clinical trials and patient care following sweeping cuts implemented by the Department of Government Efficiency (DOGE), led by President Trump and Elon Musk.

Critical Cancer Trial Halted in Pittsburgh

At the VA hospital in Pittsburgh, researchers had spent months preparing for a clinical trial of a promising new drug therapy for veterans with advanced cancers of the mouth, throat, and voice box. The trial targeted patients whose cancer had metastasized and who had exhausted all standard treatment options.
Just as the team was ready to begin enrolling patients last month, the process came to an abrupt halt. The hospital was unable to renew the position of a clinical research coordinator—a key staff member essential for the trial's operation—due to the hiring freeze imposed by the Trump administration.
"They were ready to enroll," explained Alanna Caffas, chief executive of the Veterans Health Foundation, which administers the trials. "They had the lab kits on site. They had the drug to dispense. But they couldn't get the clinical research coordinator renewed."

Widespread Impact on VA Research Programs

This case represents just one example of a broader crisis affecting the VA's research mission. Clinical trials, which offer veterans early access to cutting-edge experimental treatments, are being suspended across the system.
Rashi Romanoff, chief executive of the National Association of Veterans' Research and Education Foundations, described how the January 20 executive order freezing government hiring has cut off "many of the VA's critical research staff midway through studies," creating uncertainty for patients awaiting experimental treatments.

Staffing Cuts Affecting Core Services

The DOGE initiative has resulted in approximately 2,400 employees being fired from the VA since President Trump's inauguration. Many of these workers were responsible for essential support functions, including:
  • Purchasing medical supplies
  • Scheduling patient appointments
  • Arranging transportation for veterans to medical appointments
A significant number of those terminated were veterans themselves. All were classified as "probationary" employees, meaning they were relatively new hires with fewer legal protections. Some may potentially be reinstated pending court action.

"Chaotic Ripple Effect" Across the System

VA administrators and former workers describe a "chaotic ripple effect" stemming from the deep cuts, firings, and purchasing freezes implemented under DOGE. The disruptions have extended beyond research to affect day-to-day operations and patient care.
The situation has raised concerns even among Republican lawmakers. Senator John Barrasso (R-WY) expressed alarm about the DOGE overreach, stating, "We want to make sure veterans get the care they need."

Uncertain Future for VA Healthcare

The current disruptions threaten to undermine the VA's dual mission of providing healthcare to veterans while advancing medical research. Clinical trials not only offer veterans access to potentially beneficial experimental treatments but also contribute to broader medical knowledge.
As court challenges to some of the staffing cuts proceed, the immediate future remains uncertain for both VA healthcare providers and the veterans they serve. Meanwhile, patients like those awaiting the cancer trial in Pittsburgh are left without access to potentially life-extending experimental treatments.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Faces Turmoil: Leadership Changes and Operational Disruptions Raise Industry Concerns

The FDA is experiencing significant disruption with approximately 1,000 employees laid off, though 300 may be rehired, while 30 facilities were initially slated for closure before some decisions were reversed.
President Trump's FDA Commissioner nominee Marty Makary faced Senate questioning amid canceled vaccine advisory meetings, while other health agency nominees including Jay Bhattacharya (NIH) and David Weldon (CDC) generate controversy.

Congress's Failure to Renew Priority Review Voucher Program Threatens Rare Disease Drug Development

The FDA's rare pediatric disease Priority Review Voucher program expired in December 2023, despite unanimous congressional support for renewal, leaving biotech companies unable to receive new vouchers worth approximately $150 million.
Eleven priority review vouchers were awarded in 2023, marking a record year, with beneficiaries including treatments for sickle cell disease, Duchenne muscular dystrophy, and other rare conditions.

FDA Budget Cuts Under Trump Administration Threaten Drug Development Pipeline

Pharmaceutical companies warn in SEC filings that Trump administration's FDA staffing and budget cuts could significantly delay or halt new drug approvals and commercialization processes.
Recent layoffs of hundreds of FDA employees have sparked industry-wide concerns about disruptions to clinical trials, grant applications, and regulatory oversight activities.

FDA Accepts Nivolumab-Ipilimumab Combination for First-line Treatment of dMMR/MSI-H Colorectal Cancer

The FDA has accepted the sBLA for nivolumab plus ipilimumab combination therapy as a potential first-line treatment for MSI-H/dMMR colorectal cancer, with a PDUFA date set for June 2025.
The submission is backed by data from the phase 3 CheckMate 8HW study, offering a potential chemotherapy-free option for both adult and pediatric patients with unresectable or metastatic disease.

USAID Funding Freeze Disrupts Critical HIV Vaccine Development in Africa

A funding freeze implemented by the Trump administration has severely impacted HIV vaccine research progress in Africa, halting critical trials and scientific advancement in the region.
Program director Glenda Gray reveals that the suspension of USAID financial support has directly affected the development of potential HIV vaccines, impacting millions of patients awaiting breakthrough treatments.

USAID Funding Freeze Threatens Global Clinical Trials and Infectious Disease Research

The US Agency for International Development (USAID) has suspended all foreign assistance funding, forcing the pause of multiple clinical trials and threatening ongoing research in HIV, tuberculosis, and malaria.
Non-profit organizations like International AIDS Vaccine Initiative (IAVI) have already halted trials, while existing study participants face uncertainty about continued care and follow-up.

FDA Layoffs Threaten Drug Safety and Innovation: Experts Warn of Widespread Impact

Recent Trump administration layoffs at HHS agencies could affect up to 5,000 staff members, with significant cuts reported at FDA's device regulation office, potentially compromising public health oversight.
The dismissals specifically target probationary staff and recently promoted employees, raising concerns about the FDA's ability to handle emerging technologies and maintain regulatory expertise.

FDA Staff Cuts Impact Neuralink Trial Review Team Amid Brain Implant Oversight

Approximately 20 FDA employees from the Office of Neurological and Physical Medicine Devices, including Neuralink reviewers, were dismissed as part of a broader federal workforce reduction.
Former FDA official Victor Krauthamer expresses concerns about trial oversight and patient protection following the staff cuts in the division responsible for brain-computer interface device supervision.

FDA Halts Moderna's Norovirus Vaccine Trial Following Guillain-Barré Case

The U.S. FDA has placed a clinical hold on Moderna's late-stage norovirus vaccine trial (mRNA-1403) after a reported case of Guillain-Barré syndrome.
British pharmaceutical giant GSK faces market pressure as Citadel takes a significant short position worth 305 million pounds.

FDA Approves Monthly Maintenance Dosing for Leqembi in Early Alzheimer's Treatment

The FDA has granted approval for monthly maintenance dosing of Leqembi (developed by Eisai and Biogen) for early Alzheimer's disease patients. After 18 months of bi-weekly treatment, patients can transition to monthly dosing at half the original dose, based on Phase 2 study results and modeling simulations demonstrating sustained therapeutic benefits.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy